Sialic acids may modulate cell proliferation and gene expression, particularly in neural cells in vitro. However, the function of sialic acids in the central nervous system has not previously been examined. We examined whether N-acetylmannosamine (ManNAc) could improve object recognition and hippocampal cell proliferations in middle-aged mice. C56BL/6J mice aged 52 weeks were treated with ManNAc for 4 weeks. Their cognitive-ability was assessed with a place and object recognition test. ManNAc, but not N-acetylglucosamine or N-acetylneuraminic acid, improved the index score in the place recognition task at a dosage of 5.0 mg/mL in drinking water. Additionally, ManNAc enhanced the hippocampal cell proliferation, which was evaluated by a bromodeoxyuridine assay and the number of Ki67-immunoreactive cells. We could demonstrate that ManNAc had positive effects on the age-related brain dysfunction. These findings suggest that the use of ManNAc or related compounds may be a new approach for the treatment of human dementia.
Spatial learning and memory in aged rodents is impaired in various spatial and working memory tasks. 1, 2) The object recognition test, which is based on the spontaneous and natural preference for novelty in animals, has been used to assess the working memory ability. 3, 4) With the place recognition test, a familiar object is located in a different place from that where it had been encountered by a mouse on a prior occasion. In the latter session, animals direct more attention towards the object in the novel location. In the object recognition test, during which animals show distinctive behavior towards the unfamiliar object that replaces the familiar object, it has been demonstrated that lesions in septohippocampal projections impaired the latter but not the former. 5, 6) The neural mechanisms responsible for spatial cognitive abilities are not fully understood. A recent study has demonstrated that newly generated neurons in the dentate gyrus of the hippocampus played a vital role in spatial cognitive ability. 7) Aging and stress impair both neurogenesis and hippocampal-dependent behavioral tasks. 8, 9) Recent studies have revealed the biological roles of neurogenesis in the hippocampus in mice and rats by a variety of methods, including cytostatic drugs, brain irradiation, and genetic ablation of dividing progenitors throughout the adult brain. [10] [11] [12] These findings collectively suggest that the decline of adult neurogenesis in aged animals is the causative factor of cognitive impairments, and that therapeutic chemicals that enhance neurogenesis are prospective agents for treating age-related cognitive disorders.
Sialic acids are terminal components of the oligosaccharide chains of glycoproteins and glycolipids. These acids are 9-carbon amino sugars that are carboxylated at the C2 position and aminated at the C5 position. NAcetylneuraminic acid (Neu5Ac), which is the most common sialic acid, is the biosynthetic precursor of virtually all members of the sialic acid family.
13) The amount of sialic acid is constrained by negative feedback of the key enzyme, 2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE/MNK) which converts uridine 5 0 -diphosphate-N-acetyl-D-glucosamine (UDPGlcNAc) to 6-phosphate-N-acetylmannosamine through ManNAc. 14) Sialylation of glycoproteins and glycolipids on eukaryotic cell surfaces plays an important role in a variety of cell-cell and cell-matrix adhesion processes during development and in the pathogenesis of diseases. 15, 16) ManNAc can rescue the sialylation of glycoproteins in GNE-knockout embryonic stem cells, 17) and induce neural proliferation and dendrite outgrowth in vitro. 18) There is therefore a possibility that ManNAc can act as a signaling molecule in addition to a substrate for glycosylation 19) and can be used as a therapeutic ligand. For instance, a GNE mutation has been found in patients with distal myopathy, and this symptom was recovered by treating with ManNAc in drinking water. 20) The therapeutic efficacy of ManNAc on the agerelated decline of cognitive ability was examined in this study by an object recognition test. We compared the effects of ManNAc with Neu5Ac and GluNAc, because ManNAc can act as a signaling molecule, while the other two chemicals are metabolites of glycosylation. In addition, a hippocampal neurogenesis assessment was y To whom correspondence should be addressed. Tel: +81-42-769-1853; Fax: +81-42-850-2513; E-mail: kikusui@azabu-u.ac.jp conducted after the ManNAc treatment in order to determine whether ManNAc could stimulate cell proliferation.
Materials and Methods
Animals. C57/BL6J male mice, which were originally obtained from a breeder (Clea Japan, Tokyo, Japan) and were aged from 47 to 48 weeks (middle-aged mice), were individually housed for 4 weeks in a cage (17 Â 24 Â 12 cm). Controls, which consisted of younger mice aged 8 weeks, were obtained from the same breeder and were individually housed for 4 weeks in a cage (17 Â 24 Â 12 cm). Food and water were supplied ad libitum, and the environment was maintained at a constant temperature (24 AE 1 C) and humidity (40 AE 5%) under a 12/12-h light-dark cycle. All animal experiments were approved by the Ethical Committee of Azabu University (090305-2, approved on March 5th, 2009).
Testing procedure. Behavioral tests were conducted during the illuminated period in a soundproof room. The mice were moved into the experimental room more than 2 h before the experiment started and then placed in an open area (45 Â 45 Â 45 cm) that was bounded by gray acrylic plastic for 5 min for familiarization. After a 5-min interval, 2 objects were placed in the open area. These objects were cubes (6 cm wide) that were made of earthenware and contained visual patterns that were used for discriminating of the objects. The box and objects were cleaned with 75% of ethanol between trials so that no olfactory cues could accumulate. The mice underwent three 5-min sessions with 5-min intervals between the sessions (Fig. 1) . In the first ''sample session,'' each mouse was placed in the open area and exposed to 2-object sample stimuli (objects A1 and A2) for 5 min. The experimenter measured the total time that the mouse spent exploring each of the 2 objects, in which investigation constituted any exploratory behavior (i.e., head orientation and sniffing occurring within <1.0 cm), or deliberate contact with each object. The mouse was then returned to its home cage for 5 min. The mice were next placed back in the open area and exposed to two objects, a familiar location (A1) and an object placed in an unfamiliar location (A2) for 5 min, whose location was changed (''place session''). The experimenter again measured the total time that the mice spent exploring each of the two objects. After a second 5-min interval in the home cage, the mice were placed in the open area and exposed to one of the familiar objects (A1), which was placed in the same location, as well as an unfamiliar object (A3), which replaced A2 in the same location, for 5 min; the time spent exploring each of the two objects was measured (''object session'').
Three experiments were performed. In Experiment 1, the agerelated decline of spatial and object recognition ability was examined. Middle-aged (51 weeks of age, n ¼ 10) and young (13 weeks of age, n ¼ 10) mice were tested in the sessions just described. In Experiment 2, the dose dependence of ManNAc was examined with the middleaged mice. In Experiment 3, the effects of related chemical compounds were also analyzed with middle-aged mice.
Chemicals. N-Acetylmannosamine (ManNAc), N-acetylglucosamine (GlcNAc), and N-acetylneuraminic acid (NeuNAc) were obtained from Sanyo Fine Co. (Osaka, Japan) and N-acetylglucosamine (GlcNAc) was obtained from Tokyo Chemical Industry Co. (Tokyo, Japan). All compounds were dissolved in water at a concentration of 0.2, 1.0, or 5.0 mg/mL and administered in drinking water during the testing period. The following mice were used: Experiment 1, middleaged mice (n ¼ 10) and young mice (n ¼ 10); Experiment 2, ManNAc, 0.2 mg/mL (n ¼ 15), 1.0 mg/mL (n ¼ 12), 5.0 mg/mL (n ¼ 13), and water control (n ¼ 13); Experiment 3, ManNAc, 5.0 mg/mL (n ¼ 17), GlcNAc, 5.0 mg/mL (n ¼ 17), NeuNAc, 5.0 mg/mL (n ¼ 16), and water control (n ¼ 14); BrdU immunohistochemical studies, ManNAc, 5.0 mg/mL (n ¼ 9) and water control (n ¼ 9); and Ki67 immunohistochemical studies, ManNAc, 5.0 mg/mL (n ¼ 7) and water control (n ¼ 8).
Immunohistochemistry. Each mouse for the BrdU treatment was intraperitoneally injected with 50 mg/kg of BrdU (Millipore, Billerica, MA, USA) dissolved in saline. The mice were injected six times with BrdU: at 8:00, 10:00, 12:00, 14:00, 16:00, and 18:00. The brains were harvested 30 min after the last injection.
After an anesthetic overdose of pentobarbital (100 mg/kg. i.p.), the mice were transcardially perfused with 4% paraformaldehyde. The brains were removed, postfixed in 4% paraformaldehyde for 3 h, and stored in a 30% sucrose solution. The brains were cut by a freezing cryostat at 30 mm throughout the dorsal hippocampus. A series of 5 sections were taken as a group, and each section was processed for immunostaining. Eight sections that were 80-mm apart were stained with each staining protocol in an individual mouse. The following primary antibodies and final dilutions were used: BrdU, 1:500 (sheep polyclonal, ab1893; Abcam, Tokyo, Japan) and Ki67, 1:200 (sheep polyclonal, VP-K451; Vector Laboratories, Burlingame, CA, USA). The secondary antibodies included biotinylated anti-sheep IgG (1:3,000, BA-6000; Vector Laboratories) and biotinylated anti-rabbit IgG (1:3,000, BA-1000; Vector Laboratories).
The following DNA denaturation steps preceded incubation with the anti-BrdU antibody in order to detect BrdU-labeled nuclei in the tissue sections, a 1-h incubation in 0.01 m citric acid at 95 C, two 10-min rinses in 4.5% NaCl in a 0.1 m phosphate buffer (PBS), a 45-min incubation in 2 N HCl at 37 C, and four 10-min rinses in PBS. Sections were then treated for 2 h with 3% BlockAce blocking serum (Meiji Chemical, Tokyo, Japan). The sections were incubated in PBS overnight at 4 C with the primary antibodies, using the mixtures for double-staining described. After rinsing in PBS, the sections were incubated for 3 h with the secondary antibodies.
Immunoreactive signals were detected and processed under a BX51 fluorescent microscope (Olympus Corporation, Tokyo, Japan) equipped with a DP71 digital CCD camera (Olympus Corporation). The images were obtained with computer software (DP manager; Olympus Corporation).
The immunoreactive cells were counted in the subgranular zone, which is a 2-cell-body-wide zone along the border of the granul cell layer of the dentate gyrus and hilus, and combined with the granul cell layer. The immunopositive cell density (cells/mm 2 ) was measured as previously described. 21) Briefly, the areas of the granul cell layer and hilus on each section were determined with NIH Image 1.62 semiautomatic image analysis system (NIH, Bethesda, MD, USA). Since no statistical differences in the area of the granul cell layer or hilus were apparent between groups, no stereological corrections for sampling errors were applied.
Data analysis. The discrimination ability for the behavioral test is defined as the proportion of time the animals spent investigating an unfamiliar object in comparison with the time spent investigating the previously presented familiar object. Accordingly, place and object DI was calculated as the investigation time for the unfamiliar place and object in the test session/the same object investigation time in the previous session, as previously described. 22) This ratio served to normalize individual or group differences in the total amount of investigation time.
As statistical analysis was performed with SPSS ver. 17 (IBM Corporation, Armonk, NY, USA), differences being considered statistically significant for p values of less than 0.05. A t-test was conducted in Experiment 1 to compare the responses to familiar and unfamiliar objects. The index values for each session were additionally compared with a t-test between the middle-aged and young groups. Since the distribution of population data obtained did not fit a normal distribution ( 2 ¼ 70:44, p < 0:000001) in Experiments 2 and 3, the comparison and data expression were conducted in a non-parametric way by the Wilcoxon signed-rank test for group comparisons, within the subject design. Group differences were analyzed with the nonparametric Mann-Whitney U-test for the histochemical studies.
Results

Behavioral tests Experiment 1
The experimental mice were placed for 5 min in an open arena (45 Â 45 Â 45 cm) that was bounded by gray acrylic plastic for habituation. Two objects were placed in the open area after a 5-min interval. The mice underwent three 5-min sessions with 5-min intervals between consecutive sessions (Fig. 1a) . The young mice took a longer investigation time for the unfamiliar object in both the place (t ¼ À2:26, p < 0:05) and object sessions (t ¼ À3:58, p < 0:005, Fig. 1b) , indicating that the young mice discriminated between the familiar and unfamiliar objects in both the place and object sessions. The middle-aged mice group took an investigation time for the two unfamiliar objects that was of equal duration to the taken by the young mice in the sample session (Fig. 1c) , then they took a reduced investigation time for the familiar object in the place and object sessions. However, the duration for investigating the unfamiliar object did not differ from that for the familiar object in both place and object sessions (Fig. 1c) , suggesting that the middle-aged mice could not discriminate between the familiar and unfamiliar objects in both the place and object sessions. Significant differences were observed for both the place (t ¼ À2:10, p < 0:05) and object (t ¼ À2:77, p < 0:01) sessions (Fig. 1d) when the index values were compared between the middle-aged and young mice.
Experiment 2
ManNAc was administered to the mice in drinking water for 4 weeks to analyze the dose dependence of the compound. The behavior of the mice towards the unfamiliar object was measured before administration (Pre) and after administration (Post), and analyzed by the within subject design. The ManNAc treatment at the highest dose of 5.0 mg/mL improved the place DI (Fig. 2a , Z ¼ À2:012, p < 0:05) and object DI (Fig. 2b , Z ¼ À2:20, p < 0:05), although this improvement was not apparent with the lower doses.
Experiment 3
The ManNAc treatment at a dose of 5.0 mg/mL improved the spatial index (Fig. 3a , Z ¼ À2:57, p < 0:01), although this improvement was not apparent with 5.0 mg/mL of GluNAc or NeuNAc. No difference in effect was observed for any compound in the object session (Fig. 3b) .
Immunohistochemistry
After conducting the behavioral test, the mice were injected with bromodeoxyuridine (BrdU) and assessed by immunohistochemical staining of cells in the hippocampus. BrdU-positive cells were observed in the subgranular zone, which is a 2-cell-body-wide zone along the border of the granul cell layer (GSL) of the a, The discrimination index (DI) for the place session showed clear improvement of the task when the middle-aged mice were treated with ManNAc at a dose of 5 mg/mL, but not at other doses. b, Similarly, mice treated with ManNAc at a dose of 5 mg/mL showed improvement of the object DI, but no effect was apparent at the other doses. ManNAc, 0.2 mg/mL (n ¼ 15), 1.0 mg/mL (n ¼ 12), 5.0 mg/mL (n ¼ 13), and water control (n ¼ 13) were used. Data are presented as the median (horizontal bar) AE 25% and 75% quartiles (box) with the maximum and minimum (whiskers). Ã p < 0:05, non-parametric Wilcoxon signed-rank test.
Sample session 5min
Place session 5min
Object session 5min A subject mouse was introduced to an open area in which two objects were placed for 5 min so that the mouse could examine the objects (sample session). After a 5-min interval, the mouse was placed in the arena again, but the placement of 1 of the 2 objects had been changed, and the investigation behavior was monitored for 5 min (Place session), followed by a second 5-min interval. The subject mouse was reintroduced into the arena in which 1 of the objects had been replaced by an unfamiliar object, and the exploring behavior was monitored for 5 min (object session). b, Investigation time by the young mice (n ¼ 10). The mice showed distinctive investigational behavior towards the unfamiliar object in both the place and object sessions. c, In contrast, middleaged mice (n ¼ 10) did not show any distinctive investigational behavior towards either the familiar or unfamiliar object. d, When the index was calculated as place and object discrimination index (DI) (the investigation time for the unfamiliar place and object in the test session/the same object investigation time), the middle-aged mice showed a decrease in the index of both place and object sessions. Data are presented as the mean þ SEM.
Ã p < 0:05, t-test.
dentate gyrus and the hilus, and in GSL (Fig. 4a) . The density of the BrdU-positive cells in the ManNActreated group was higher than that in the water-treated control group (Fig. 4c , Z ¼ 2:25, p < 0:05). Similarly, Ki67-positive cells were apparent in the subgranular zone of the dentate gyrus, the hilus, and GSL (Fig. 4b) . The density of Ki67-positive cells in the ManNAc-treated group was higher than that in the water-treated group (Fig. 4d , Z ¼ 2:08, p < 0:05).
Discussion
The age-related decline of spatial and object recognition was recovered by treating with ManNAc in the present study. Increased cell proliferation in the hippocampus was also apparent. These results demonstrate that activating the biosynthesis of such sialic acid, as ManNAc could potentially be used to improve cognitive impairment and dementia in aged animals, including humans. A clear improvement in recognition was detected in the place recognition task, although the effect was not stable in the object recognition task. This was probably due to the large individual difference in response to the ManNAc treatment with the object recognition task. The reason for this is so far unclear, but one possibility is that the two tasks were dependent on different neural mechanisms. Some studies have demonstrated that these two tasks were indeed dependent on different neural mechanisms; place recognition was sensitive to the age-related decline of cognitive abilities and depends on hippocampal function. 5, 6, 22, 23) Hippocampal lesions have been shown to impair novel location recognition in experiments that examined whether rats recognized a change in the configuration of five objects in an open area. 24) Object recognition in a two-object paradigm was unaffected by fornix lesions: 6) in contrast, object recognition was dependent on the nerve growth factor (NGF) and the cholinergic system. An Alzheimer's disease model of AD11 mice, which expressed recombinant antibodies that neutralized the biological activity of NGF, has shown progressive neurodegeneration that was characterized not only by atrophy of basal forebrain cholinergic neurons and the nucleus of Meynert, 25) but also showed impairment in the object, but not the place, recognition test.
26) The ManNAc treatment may therefore have improved the hippocampal function, rather than the cholinergic deficits, in middle-aged mice.
Neural progenitors persist throughout life in the subgranular zone (SGZ) of the dentate gyrus and continuously give rise to new neurons. 27 ) Newborn granul cells become mature granule cells that are indistinguishable from granule cells that are born during embryonic development. 28, 29) Newborn granule cells integrate into the preexisting dentate circuitry after an activity-dependent selection process. 28, 30, 31) Recent studies have uncovered the biological role of neurogenesis in the hippocampus. When new granule cells mature, they are incorporated into neural circuits that are activated during spatial memory tasks. Interestingly, this functional maturation of newly generated cells, which takes four or more weeks, results in cells that are more likely than existing granule cells to be recruited into circuits supporting spatial memory. 7) Middle-aged mice were treated with ManNAc for 4 weeks in this present study, and place recognition was improved. Our preliminary data showed that 2 weeks of ManNAc administration had no effect on place recognition (data not shown), suggesting that the neurogenesis induced by the ManNAc treatment for more than 4 weeks is the mechanism responsible for the increase in place recognition. Adult neurogenesis in genetically engineered mice has been enhanced in other studies, and these mice showed improved pattern recognition. 12) One possibility is therefore that the cognitive improvement induced by the ManNAc treatment was mediated by an increase in neurogenesis in the hippocampus.
The mechanism for ManNAc-induced cell proliferation remains to be elucidated. Cell proliferation, especially hippocampal neurogenesis, is enhanced by several factors, including such physical activity, as running, or rearing in an enriched environment. 30, 32) Aged rats have shown decreased neurogenesis that was accompanied by impaired learning and memory. 8, 9) This decline of neurogenesis in aged animals was recovered by physical activity (running) or environmental enrichment. 33, 34) The observed increase in cell proliferation following the treatment with ManNAc may therefore be mediated by increased physical activity or rhythmic locomotion, making it necessary to monitor the activity level in the ManNAc-treated mice. Another mechanism involves direct ManNAc-stimulated cell proliferation at the cellular level. Such genes as mbd1, fgfr1, NT-3, and BDNF have been demonstrated to be related to the a, The discrimination index (DI) of the place session showed clear improvement of the task after the middle-aged mice had been treated with ManNAc, but not following treatment with the other chemical compounds. b, In contrast, no effect was apparent in the object session. ManNAc, 5.0 mg/mL (n ¼ 17), GlcNAc (n ¼ 17), NeuNAc (n ¼ 16), and water control (n ¼ 14) were used. Data are presented as the median (horizontal bar) AE 25% and 75% quartiles (box) with the maximum and minimum (whiskers).
Ã p < 0:05, non-parametric Wilcoxon signed-rank test. maintenance of neurogenesis, and conditional knockout of these genes in mice has resulted in the inhibition of neurogenesis. 27, [35] [36] [37] In contrast, neurokinin1-knockout mice have shown increased neurogenesis.
38) The primary target molecule of ManNAc has not been determined; an analysis of the expression of these genes/proteins should be conducted in the future.
We have shown that 5 mg/mL of ManNAc, but not of GlcNAc or NeuNAc, improved the cognitive deficit in middle-aged mice, although it remains unclear whether or not other doses of GlcNAc or NeuNAc would be effective on the spatial recognition of middle-aged mice. In vitro studies have indicated that ManNAc and not GlcNAc had the ability to promote sialic acid production under conditions involving GNE deficiency, suggesting that the phosphorylation of ManNAc was mediated by another kinase. 17) NeuNAc, a strong GNE inhibitor, may have a negative impact on sialylated protein production with prolonged exposure. In contrast, ManNAc can promote sialic acid production, even in GNE-mutant mice. 20) The results obtained in this study therefore suggest that ManNAc, which is a strong promoter of sialic acid production, would increase neurogenesis and cognitive ability more than sialic acid itself. Further studies are needed to determine the neurobiological role of ManNAc in cell proliferation or gene expression in aged animals. 39) In summary, the ManNAc treatment had a positive effect on neurogenesis in the hippocampus, as well as on improved object recognition by middle-aged mice.
However, the underlying molecular mechanisms for these observations remain unresolved. Further studies are also needed to clarify the pharmacological characteristics of ManNAc: for example, the effects on long-term memory and reference memory, the effects on aged mice and young mice, and the length of the treatment period. Our results suggest that ManNAc or related compounds can be used to treat age-related cognitive dysfunctions in humans. . c, The number of cells that were immunoreactive to BrdU was higher with the ManNAc-treated mice (n ¼ 9) than with the water-treated mice (n ¼ 9). d, Similarly, the number of cells that were immunoreactive to Ki67 was higher with the ManNAc-treated mice (n ¼ 7) than with the water-treated mice (n ¼ 8). Data are presented with mean þ SEM.
Ã p < 0:05, non-parametric Mann-Whitney U-test.
